Zosano Pharma Corp (NASDAQ:ZSAN) Director Kenneth Greathouse acquired 95,000 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The shares were bought at an average price of $0.62 per share, for a total transaction of $58,900.00. Following the completion of the purchase, the director now owns 95,000 shares of the company’s stock, valued at $58,900. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Kenneth Greathouse also recently made the following trade(s):
- On Wednesday, November 15th, Kenneth Greathouse acquired 50,000 shares of Zosano Pharma stock. The shares were bought at an average price of $0.62 per share, for a total transaction of $31,000.00.
Shares of Zosano Pharma Corp (ZSAN) opened at $0.58 on Tuesday. Zosano Pharma Corp has a one year low of $0.56 and a one year high of $3.54.
Zosano Pharma (NASDAQ:ZSAN) last issued its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.05). equities analysts expect that Zosano Pharma Corp will post -0.79 earnings per share for the current year.
An institutional investor recently raised its position in Zosano Pharma stock. Vanguard Group Inc. boosted its holdings in Zosano Pharma Corp (NASDAQ:ZSAN) by 20.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,217,323 shares of the biotechnology company’s stock after acquiring an additional 209,251 shares during the quarter. Vanguard Group Inc. owned about 3.11% of Zosano Pharma worth $1,716,000 as of its most recent SEC filing. 19.68% of the stock is currently owned by hedge funds and other institutional investors.
Separately, ValuEngine upgraded shares of Zosano Pharma from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st.
TRADEMARK VIOLATION NOTICE: “Zosano Pharma Corp (ZSAN) Director Kenneth Greathouse Acquires 95,000 Shares” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/05/zosano-pharma-corp-zsan-director-kenneth-greathouse-acquires-95000-shares.html.
Zosano Pharma Company Profile
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
Receive News & Ratings for Zosano Pharma Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corp and related companies with MarketBeat.com's FREE daily email newsletter.